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Abstract
Temper outbursts are a severe problem for people with Prader-Willi Syndrome (PWS). Pre-
vious reports indicate that vagus nerve stimulation (VNS) may reduce maladaptive behav-
iour in neurodevelopmental disorders, including PWS. We systematically investigated the
effectiveness of transcutaneous VNS (t-VNS) in PWS. Using a non-blind single case repeat
measures modified ABA design, with participants as their own controls, t-VNS was evalu-
ated in five individuals with PWS [three males; age 22–41 (M = 26.8)]. After a baseline
phase, participants received four-hours of t-VNS daily for 12 months, followed by one month
of daily t-VNS for two-hours. The primary outcome measure was the mean number of beha-
vioural outbursts per day. Secondary outcomes included findings from behavioural ques-
tionnaires and both qualitative and goal attainment interviews. Four of the five participants
who completed the study exhibited a statistically significant reduction in number and severity
of temper outbursts after approximately nine months of daily four-hour t-VNS. Subsequent
two-hour daily t-VNS was associated with increased outbursts for all participants, two reach-
ing significance. Questionnaire and interview data supported these findings, the latter indi-
cating potential mechanisms of action. No serious safety issues were reported. t-VNS is an
effective, novel and safe intervention for chronic temper outbursts in PWS. We propose
these changes are mediated through vagal projections and their effects both centrally and
on the functioning of the parasympathetic nervous system. These findings challenge our
present biopsychosocial understanding of such behaviours suggesting that there is a single
major mechanism that is modifiable using t-VNS. This intervention is potentially
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generalizable across other clinical groups. Future research should address the lack of a
sham condition in this study along with the prevalence of high drop out rates, and the poten-
tial effects of different stimulation intensities, frequencies and pulse widths.
Introduction
Prader-Willi Syndrome (PWS) is a genetically determined neurodevelopmental disorder with
a birth incidence of one in 25,000–29,000.[1] At least 80% of people with PWS are reported to
have severe temper outbursts from childhood into adult life.[2,3] These behaviours have a sig-
nificant effect on the level of independence and quality of life of those with PWS and impact
those who support them.[4]
PWS results from the absence of paternal expression of maternally imprinted genes at chro-
mosomal locus 15q11-13, resulting from either a paternal interstitial deletion (delPWS; 70% of
cases), maternal uniparental disomy (mUPD; 25%), or less commonly, an imprinting centre
defect (3–5%) or an unbalanced translocation (<5%).[5] All genetic types of PWS are character-
ised by infantile hypotonia, hypogonadism, early failure to thrive, mild to moderate intellectual
disability, distinct facial characteristics, short stature, and small extremities.[6] PWS also has a
characteristic behavioural phenotype that includes a marked propensity to severe temper out-
bursts, the onset of severe hyperphagia in early childhood that results in life threatening obesity
if food access is not controlled, repetitive and ritualistic behaviours, and skin picking.[2,3]
The reasons for chronic and lifelong temper outbursts in PWS are uncertain. The impact of
developmental delay,[2] shaping of such behaviours through reinforcement, and a deficit in
attention shifting, whereby unexpected changes in routine or expectations generate high cog-
nitive demand, may all predispose to this high propensity for outbursts.[3,7–9] Presently, treat-
ments are informed by a biopsychosocial perspective but often limited to the ad-hoc use of
psychiatric medications and behavioural approaches that aim to reduce outburst frequency
and severity, together with better management when they do occur. Given the adverse impact
and the limits of present interventions the development of effective interventions is a high
priority.
Recent unanticipated observations in a study of three adults with PWS[10] suggests a possi-
ble novel and effective intervention: vagus nerve stimulation (VNS). Using implanted devices,
this study investigated whether VNS might reduce hyperphagia. Whilst no reduction in hyper-
phagia was found, improvements in problem behaviours were reported by two of the three
participants who had a history of problem behaviours, and also by their carers. Anecdotally,
these behavioural improvements had a notable effect on participants’ quality of life and the
two participants asked to continue with the VNS activated after the end of the study and
behaviour problems have remained very much improved over the last five years. Importantly,
no significant side effects or safety issues have been reported.
VNS has been used primarily to treat epilepsy with reports indicating beneficial effects on
behaviour and cognitive functioning, changes not explained by improved seizure control.
[11,12] Similar beneficial effects of VNS have been demonstrated in people with neurodevelop-
mental disorders, including case studies reporting improvements in mood and reduction of
aggressive outbursts in participants with ASD and epilepsy, independent of seizure control.
[13–15]
The primary aim of this study was to investigate the efficacy of VNS using an externally
worn stimulator (transcutaneous vagus nerve stimulation, t-VNS), as a therapy for temper
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outbursts in PWS. Secondary aims were: a) to study the acceptability and tolerance of t-VNS,
and b) to investigate the profile of response and possible mechanisms in order to identify
markers predictive of any change, so as to inform future trials and ultimately clinical practice.
This paper reports the outcomes of the intervention. Underlying mechanisms of action are the
subject of on-going investigation and will be reported in a subsequent paper.
Methods
East of England–Cambridge Central Research Ethics Committee (15/EE/0450) granted ethical
approval. The study was registered as a clinical trial (NCT03689621) retrospectively due to the
ethics committee at the beginning of the study defining it as a ‘clinical investigation’ not ‘clini-
cal trial’. To adhere to the ethics committee’s regulations, the study was registered on the publi-
cally accessible NIHR UK Clinical Research Network (registration number: CMPS20829). The
authors confirm that all on-going and related trials for this intervention are registered.
A repeated measures modified ABA design case series using quantitative and qualitative
outcome measures with participants as their own controls was undertaken. A randomised trial
with a blinded condition was not possible as the recommendation for t-VNS use requires par-
ticipants to set the stimulation level so as to experience a tingling sensation in the ear. A base-
line period with treatment continuing as usual for a minimum of four months was followed by
an active treatment phase of initially six months, later extended to 12 months. If no benefits
were observed the study would cease at this point. In the event of observed improvements in
behaviour ethical approval was given for a reduction in stimulation time by 50% to determine
whether benefits would be maintained at this lower level. However, if temper outbursts
returned during this phase, given their potential severity, it was considered unethical not to re-
establish the stimulation time at the recommended level if the participants so requested. Partic-
ipants who experienced improvements in behaviour were also given the option to continue t-
VNS after study completion. During data collection participants lived in their usual places of
residence.
Participants
The inclusion and exclusion criteria and subsequent participant selection are shown in Fig 1.
Recruitment was through the Prader-Willi Syndrome Association UK, local clinical services,
social care providers supporting people with PWS, and individuals and their families who had
previously consented to be contacted about research and known to author AJH.
Procedure
t-VNS was delivered in accordance with approved protocols for the treatment of epilepsy via a
battery-operated stimulator (Cerbomed NEMOS1) connected to an earpiece containing two
hemispheric titanium electrodes providing mild electrical stimulation to the cymba conchae of
the left ear. In the initial training session, participants and their carers were trained to use the
device. Stimulation intensity was increased by 0�1mA steps, from 0�1mA up to a maximum
possible 5mA, using a pulse width of 250μs at 25 Hz, until the participant reported a just
detectable tingling sensation.[16] t-VNS was worn but switched off during baseline. For the
active phase stimulation intensity was adjusted by the participants as previously instructed and
worn for four-hours each day. Participants were advised to complete daily stimulation in one
four-hour stretch or hourly or two-hourly intervals, and encouraged to incorporate use into
their daily routine, but not during sleep. Stimulation history recorded by the device allowed
compliance to be verified.
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Measures of behaviour
Deviations from the original protocol. Measures of response to challenge (methodology
developed previously by author, CO) were initially tried, but are not reported in this paper as
no participant found the task challenging enough for it to be effectively completed. The behav-
iour problems inventory[17], Aberrant Behaviour Checklist[18], and the personal wellbeing
index[19] were not completed by carers due to carers having limited time available to them
during monthly visits by the researcher.
Informant reported temper outbursts. The primary outcome measure was the mean
number of temper outbursts per day operationally defined as problem behaviours that escalate
to include physical and/or verbal aggression. Carers were asked to record these behaviours in
daily behaviour diaries. This method of data collection has been validated by Oliver et al.[20],
and can be undertaken in residential or home settings. Support staff and/or family members
Fig 1. Consolidated Standards of Reporting Trials (CONSORT) flow chart. CONSORT flow chart illustrating all
steps in the study from enrollment to allocation and follow up. Inclusion and exclusion criteria are also specified.
https://doi.org/10.1371/journal.pone.0223750.g001
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were already very informed about such behaviours as they had observed them on a regular
basis but at the time of recruitment, they were also trained in the definition of outbursts and in
using the behaviour diaries. Carers were asked to record daily each time an outburst occurred
and to give a detailed description including information on triggers, duration and intensity
rating on a 1–5 Likert scale.
Behaviour diaries were used for the duration of the study for three participants (009, 010
and 011). However, due to a high proportion of missing entries early in the study for 003 and
005 (residing in the same setting), detailed daily observation records routinely and mandator-
ily completed by carers at the residential home were used instead with ethical approval and the
participants’ permission. These routinely collected daily observation records detailed the
occurrence of problem behaviours, events leading up to, during, and after the behaviour, and
the response necessary. For consistency, these records were used throughout baseline and
active phases of the study for these two participants and coded using directed qualitative con-
tent analysis,[21] with coding categories informed by the daily behaviour diary operationally
defined criteria. A 10% sample were rated by two raters. Kappa values of above 0�9 were estab-
lished for all diary entry criteria for participants 003 & 005, indicating good inter-rater reliabil-
ity. In the current study, only the occurrence and date of temper outbursts were consistently
reported by carer’s, whereas information on triggers, duration, intensity and detailed descrip-
tions of temper outbursts from the daily behaviour diaries were not consistently completed
and are therefore not described further.
Informant questionnaire. The Challenging Behaviour Interview (CBI)[20] was con-
ducted approximately monthly at participants place of residence as a secondary behavioural
outcome measure. The CBI is a structured informant interview that includes questions about
the frequency, intensity and impact of behaviours in the previous month and is separated into
two sections. Section I documents the occurrence of defined challenging behaviours. Section II
records assessments of severity of the behaviours identified in Section I using fourteen ques-
tions, each with their own 4-5-point Likert scale (S1 Appendix).
Semi-structured interviews. Two semi-structured interviews were conducted with partic-
ipants and their carers at home: once in the baseline phase and once toward the end of the
active phase. Interview schedules (S2–S5 Appendices) comprised key questions about partici-
pants’ temper outbursts. These questions were supplemented by prompts from the interviewer,
dependent on the interviewees’ responses.
Measures of safety. Due to reports of VNS worsening sleep apnoea,[22] sleep was moni-
tored at the Wellcome Trust Clinical Research Facility (CRF) at Addenbrooke’s hospital Cam-
bridge to ensure safety in respect to sleep apnoea using a SomnoscreenTM plus RC system
(SOMNOmedics, Germany) twice during each phase.
Measure of goal attainment. Goal attainment scaling light[23] (GAS-light) was con-
ducted with carers at home. This measure was added to the original protocol to provide an
assessment of t-VNS’s impact beyond that of improved behaviour, specifically, participants’
quality of life and care demands. Baseline scores were retrospectively allocated as -1 to allow
for deterioration. Goal attainment was rated at the end of the study. Using Kiresuk & Sher-
man’s[24] formula, attainment levels were combined to make a single T-score.
Analysis overview
Informant reported temper outbursts. Previous VNS literature suggests a delayed onset
of improvements in seizure control when used for treating epilepsy and also in behavioural
improvements, ranging from three to twelve months post VNS switch on.[13–15] Therefore,
for the purpose of analysis, the active phase for each participant was divided into segments of
Transcutaneous vagus nerve stimulation (t-VNS) and temper outbursts
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three months with the aim of establishing if behaviour improves, when it does, and whether all
participants improve at a similar time. Participant data was initially pooled into baseline, active
phase 1, active phase 2, active phase 3 and active phase 4 groups. A Friedman test was used to
determine the significance of group differences in baseline and active phase segments. If a sta-
tistical difference was found, a Dunn test with Bonferroni correction evaluated any differences.
Since participants lived under different conditions, and whilst all struggled with problem
behaviours, the exact characteristics of these behaviours were varied across participants, and
for these reasons a single case design was also used with each participant as their own control.
Kruskal-Wallis tests were used to evaluate differences in the mean number of outbursts per
day at baseline and in each of the three monthly active phase segments for each participant
[25]. When a statistical difference was found, a Dunn test with Bonferroni correction was used
to assess the significance of these differences.
To evaluate the effect of reducing t-VNS duration by 50%, a Mann-Whitney U test assessed
differences between the mean number of outbursts per day in the two-hour t-VNS phase and
the last segment of the active phase.
Informant questionnaire. A Mann-Whitney U test compared the total CBI scores for
Section II during the baseline phase and each three-months of the active phase.
Semi-structured interviews. Thematic analysis was carried out following Braun and
Clarke.[26] Themes were inductively defined from the raw interview data. Step one involved
the researcher familiarizing oneself with the data by re-reading the interview transcripts sev-
eral times. In step two, open coding was applied to generate initial codes. Similar codes were
then collated into categories. In step three, categories and codes were organized into overarch-
ing themes which, as per Braun and Clarke,[26] denoted patterned response and/or meaning
within the data. Step four involved reviewing, modifying and developing the themes, ensuring
all themes were distinct from one another and coherent within the context of the entire data-
set. Step five involved defining and naming the themes to communicate succinctly what they
concerned. Step six involved producing a report of the analysis, as outlined in the Results.
To demonstrate the robustness and legitimacy of the themes generated, interview extracts
are presented in the Results.[26] To ensure validity of results a number of steps were taken: (a)
at the time of analysis, the researcher undertaking the analysis (JABW) was experienced in
qualitative research, but a novice in PWS and temper outburst research, encouraging the
investigation of novel insights; (b) the number of occurrences of each identified theme were
totaled to indicate the relative importance of each theme; (c) identified themes were theoreti-
cally validated by comparing them with literature on temper outbursts in PWS (see
discussion).
Results
Participant recruitment and retention are shown in Fig 1. Recruitment began on 1st January
2016 and follow-up and study end was on 1st April 2018. Results reported here concern the
five participants who completed the study. The demographics, prescribed medications and
length of time in each phase for participants are listed in Table 1.
Compliance
During the active phase, all participants received t-VNS for at least 86% of total possible stimu-
lation time of four hours per day for 360 days [003 (86%); 005 (100%); 009 (93%); 010 (98%);
011 (88%)]. In the two-hour stimulation phase, all participants completed at least 100% of the
specified stimulation duration [003 (100%); 005 (108%); 009 (102%); 010 (100%); 011 (105%)].
Transcutaneous vagus nerve stimulation (t-VNS) and temper outbursts
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Safety
No unexpected events were reported. Mild skin irritation surrounding the electrode was
reported in one case, which resolved within two weeks and did not impact usage. No effect on
sleep apnoea was observed.
Efficacy
Number of temper outbursts. Initially, mean number of temper outbursts per day were
analysed at group level. In SPSS, a Friedman test revealed a significant difference between tem-
per outbursts in the study phases, χ2 (4) = 14.10, p = .007. Dunn-Bonferroni post hoc tests
were carried out and there were significant differences between baseline and active phase four
(p = .014, d = 1.01) and active phase one and active phase four (p = .014, d = 1.01) after Bonfer-
roni adjustments.
Fig 2 shows the mean number of temper outbursts per day in the baseline and active
phases for each participant. Mean number of temper outbursts per day were then analysed
for each individual participant. In SPSS, using the Kruskal-Wallis test a statistically signifi-
cant difference was found between baseline and active phase four for 003, 005, 010 and
011 [003 (p =<�001, d = �18); 005 (p = �013, d = �16); 010 (p = �007, d = �21); 011 (p = �028,
d = �18)]. Participant 009 showed no significant difference in temper outbursts between the
baseline and active phases (p = �679).
Informant questionnaires. Behaviours present in section I and the mean total CBI scores
for section II during the baseline and active phase four for each participant are shown in
Table 2. In SPSS, a Mann-Whitney U tests revealed a statistically significant reduction in CBI
scores from baseline to active phase four for 003, 005, 010 and 011. [003 (p = �02); 005 (p =
�046); 010 (p = �022); 011 (p = �028)]. No significant change was observed for 009 (p = �471).
Observations of participant behaviour:. Thematic analysis identified ten sub-themes
from the semi-structured interviews with carers and participants (Table 3). These sub-themes
Table 1. Participant demographics and medications.
Sex Age (yrs.) Genetic subtype Duration of BL (months) Duration of Active (months) Medication
003 M 24.0 delPWS 8 12 Beclometasone nasal, 50mcg, BD
Sodium cromoglicate eye drop, 2%, QDS
Somatotropine injection, 0.4mg, NOCTE
Fexofenadine, 180mcg, OM
Risperidone, 1mg, 18:00
005 M 23.11 delPWS 10 12 Fluoxetine, 40mg, 08:00
Lamotrigine, 2x 25mg, 08:00 & 18:00
�Lorazepam, 2x 1mg, PRN
009 M 41.3 delPWS 5 12 Duolexetine, 30mg, 17:00
Quetiapine, 25mg, PM
Risperidone, 2x .125ml, AM & PM
010 F 23.8 delPWS 5 12 Keppra, 2x 500mg, AM & PM
Metformin, 2g, PM
Forxiga, 10mg, PM
Atorvastatin, 20mg, daily
Gliclazide, 40mg, 2x AM & 1x PM
011 F 21.8 delPWS 5 12 Vitamin D, 1000 units, daily
Somatotropin, 1.2mg, PM
Loestrin 20, x1, daily for 21 days then 7 day break
Age (years. months) at first day of baseline; delPWS, paternal interstitial deletion; BL, baseline phase; month, 30 days; Medication, name, dosage, time administered.
� change in medication at day 84 of 246 baseline phase.
https://doi.org/10.1371/journal.pone.0223750.t001
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were organised into three overarching themes; Control of emotions; Interactions with envi-
ronment/setting; and Regulation of behaviour (S6 Appendix).
In the active compared to baseline phase, informants reported an increased ability to regu-
late emotions described in terms of reduced rash emotional responses and behavioural volatil-
ity. This improved emotional control was described as facilitating regulation of behaviour and
resulting in an increased ability to process a situation and listen to advice, allowing the person
with PWS to benefit from interventions (verbal prompts etc.). As a consequence of these
reported improvements, participants’ abilities to manage and respond well to conditions that
would have previously triggered a temper outburst improved, resulting in less frequent and
lengthy temper outbursts.
Stimulation parameters
Temper outbursts during reduced t-VNS duration. All four participants showing
improvement reduced their use of t-VNS from four to two hours per day after 12 months of
active stimulation. Although 009 had not shown a significant improvement in behaviour some
changes had been described and for this reason his daily use of VNS was initially reduced
rather than just stopped. A Mann-Whitney U test revealed that in the two-hour t-VNS phase
003 and 005 displayed significantly more temper outbursts than in active phase four (Fig 3).
No significant difference was found for 009, 010 or 011 (Fig 3). However, carers reported 010
and 011 as more irritable and unable to be reasoned with during the reduced t-VNS phase
compared to active phase four. For 009 a numerical increase in temper outbursts was reported
in behaviour diaries and anecdotally by carers during this reduction phase. After one month
on two-hour stimulation all participants asked to increase the stimulation back to four-hours
per day. In line with what had been approved by the ethics committee all had their stimulation
time increased and all four who improved chose to continue on the t-VNS after the study
ended and were referred to their General Practitioner for subsequent monitoring.
Fig 2. Mean number of temper outbursts per day in each phase for each participant. BL, baseline phase; A1, first three months of active phase; A2, second three
months of active phase; A3, third three months of active phase; A4, fourth three months of active phase. Pairwise comparisons Dunn test. BL compared to A4: 003 (p =
�009); 005 (p = �021); 010 (p = �009); 011 (p = �045). A1 compared to A4: 003 (p = �003); 011 (p = �034).
https://doi.org/10.1371/journal.pone.0223750.g002
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Goal attainment scores. Table 4 shows the GAS-light T-scores for each participant. There
was a numerical increase in T-scores for participants 003, 005, 010 and 011. There was no
change in T-scores for 009.
Discussion
This is the first study to systematically investigate the use of t-VNS to ameliorate the temper
outbursts and related behaviours in PWS. Participants received VNS via an externally worn
device, rather than a surgically implanted device as has previously been reported[10], and
behaviour was recorded both contemporaneously in a naturalistic environment and in
retrospect using informant questionnaires and interviews. Our results show that t-VNS was
associated with significant reductions in temper outbursts in four out of five participants,
underpinned by improvements in emotional control, improved responses to interventions and
increased ability to effectively manage previously outburst-stimulating situations. Reduced
severity and impact of challenging behaviour was also demonstrated in these four participants.
Temper outbursts in PWS begin in childhood and continue into adult life[2], having a severe
effect on quality of life of people with PWS and their carers. This level of reduction in occur-
rence and severity of these behaviours is significant. These findings concur with previous
reports suggesting that VNS reduces maladaptive behaviour in PWS[10] and other neurodeve-
lopmental disorders.[13–15] No new side effects were reported, suggesting that the safety pro-
file in PWS is similar to VNS for epilepsy. Moreover, improvements in GAS-light scores
indicate reduced care demands and improved quality of life for participants, with carer expec-
tations of the intervention being exceeded for all participants who improved.
Initial interviews revealed that a key trigger for temper outbursts in all participants was
change, as is reported in previous literature.[3,7–9] All participants who displayed fewer
temper outbursts after t-VNS reported improvements in behavioural flexibility and ability to
Table 2. Types of behaviour’s present and mean total CBI scores for each participant in baseline and active phase 4 as reported in the CBI, and percentage of days t-
VNS was worn by each participant.
Behaviours Present Mean total CBI scores per phase
BL A4 BL A4 P a
003 Verbal aggression;
Physical aggression;
Destruction of property;
Self injury;
Stereotyped behaviours;
Stealing
Verbal aggression 31.67
(15.07)
2.67
(4.62)
0.02
005 Verbal aggression;
Physical aggression;
Destruction of property;
Self injury;
Stereotyped behaviours;
Verbal aggression 24.67
(5.51)
1.67
(2.89)
0.046
009 Verbal aggression Verbal aggression 11
(1.83)
15.67
(8.14)
0.471
010 Verbal aggression 15.6
(2.97)
0
(0)
0.022
011 Verbal aggression;
Physical aggression;
Stealing
19
(5.1)
0
(0)
0.028
BL, baseline; A4, active phase 4; Active, entire active phase of 4-hours daily stimulation
a P-value of Mann-Whitney U test comparing total CBI scores between baseline and active phase 4 for each participant.
https://doi.org/10.1371/journal.pone.0223750.t002
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accept change. Increased responsiveness to interventions aimed at placating participants prior
to a potential temper outburst was also reported.
The observation of statistically significant behavioural improvements occurring by approxi-
mately month nine of the active phase indicates a mode of action that requires time to develop,
in line with behavioural improvements observed in people with ASD and epilepsy.[13–15]
Table 3. Selected examples of verbatim quotes for each identified theme.
Study
Phase
Sub-theme Verbatim Quotes
Baseline Uncontrolled mood "He is very, very aggressive, extremely anxious, and it’ll be over
something very, very small, maybe he couldn’t find his telephone"
[VNS005]
"..there’s no rhyme or reason for her mood sometimes . . .we only need
to say one careless comment . . .and it will escalate suddenly" [VNS010]
Rigidity "As long as he is aware of what he’s doing. . . he’s fine, if there’s a
change. . .that can really upset him, he can become quite agitated and
anxious" [VNS003]
"She likes to have total control and when she feels that what we are
saying or doing is taking away even a fraction of that control that is
enough to send her into meltdown" [VNS010]
Necessity for planning ". . .So as long as he’s prepped before, if we can, then it does limit
[temper outbursts]" [VNS003]
"She only becomes angry when things don’t go as planned" [VNS011]
Behaviour impacts everyday
life
"Does his behaviour affect his own plans and activities at all, does it
disrupt them of delay them?"—"It can delay them" [VNS003]
"We don’t like doing it [taking participant out for meals] because that is
always a distinct possibility of having a flashpoint [of behaviour] there
because of the choice of what’s on the menu" [VNS010]
No opportunity for
intervention
"She shuts down. I don’t know if she can actually process what you’re
saying to her" [VNS010]
" . . .there’s just no reasoning with her. . ." [VNS011]
Active Reduced outbursts ". . .so before . . .it [a temper outburst] could go on for like two, three,
four plus hours, and now it’s literally like quick outburst . . .and then he
sort of stops and, and sort of thinks a little bit" [VNS005]
"in the last five months or four months . . .it [a temper outburst] seems
to have been far less often..they’re lasting fewer minutes than they used
to I think" [VNS010]
Controlled mood ". . .before it could be the slightest little thing. . .y’know scream shout . . .
now if you say to him “[3] it’s just gonna be five minutes y’know we’re
almost there”, he goes ’OK I’ll wait‴ [VNS003]
" . . .she came over to me and we just talked about it and I explained it
in a different way and she calmed. . .she just seemed to accept it which a
few weeks ago I don’t think she would have" [VNS011]
Flexibility " . . .any changes, anything slight would trigger his anxiety’s off, umm
since he’s been on the VN we’ve seen a massive change in [participant].
He’s a little bit more tolerant with timing" [VNS003]
"she’s accepting more changes now than she used to I think. . .without a
fuss" [VNS010]
Behaviour positively impacts
everyday life
"If he’s too heightened then obviously it may deem unsafe for him to
go. . .we haven’t had to do something like that with [participant] for the
last six months" [VNS003]
"I think she’s happier in herself . . . she’s not falling out with [friend] as
much as she used to" [VNS010]
Opportunity for intervention " . . .before you couldn’t challenge him on certain things, where you
needed to, but now you can and he’s prepared to sit and listen"
[VNS003]
"I think we’ve got more breathing space because she often doesn’t react
immediately. . .it can give you time to think . . .of some way of
distracting her or diffusing the situation" [VNS010]
https://doi.org/10.1371/journal.pone.0223750.t003
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However, lower compliance for 003, 010 and 011 early in the active phase may have contrib-
uted to later onset of improvement. This finding, combined with the observation that a 50%
reduction in stimulation time resulted in an increase in outbursts, indicates that continued
stimulation at the initial level is required to maintain a therapeutic effect.
It is unclear why 009 did not show behavioural improvement. However, at 41 years, 009
was older than other participants. Research on behaviour in older adults with PWS over the
age of 30 is scarce but does indicate a changing profile with reduced outburst-related behav-
iours with age.[27] A specific functional reinforcement of outbursts for 009 may also be impli-
cated, with desired one-to-one care only accessed when necessitated by such behaviours. The
behaviours displayed by 009 were no worse than others but it was of note that he had been pre-
scribed the highest doses of antipsychotic medications compared to all other participants.
Fig 3. Mean number of temper outbursts per day during active phase 4 and 2-hour stimulation phase. A4, last
three months of active phase; 2-hour, t-VNS worn for 2-hour in this stimulation phase. P-values of Mann-Whitney U
test: 003 (p = �000); 005 (p = �001).
https://doi.org/10.1371/journal.pone.0223750.g003
Table 4. GAS light values for each participant in baseline and active phase 4.
GAS light values
Goal 1a Goal 2b Goal 3c T-score
BL A4 BL A4 BL A4 BL A4
003 -1 2 -1 2 -1 1 36.3 68.3
005 -1 2 -1 2 -1 1 36.3 68.3
009 -1 -1 -1 -1 -1 -1 36.3 36.3
010 -1 2 -1 2 -1 1 36.3 72.8
011 -1 1 -1 1 -1 1 36.3 63.7
BL, baseline; A4, active phase 4. Attainment for each goal was rated where: 0, expected level of achievement; +1, a
little better than expected; +2, a lot better than expected; -1, no change; -2, worsening. T-score derived from Kiresuk
& Sherman’s formula.[24]
a Goal 1, reduce number of temper outbursts for the participant
b Goal 2, improve the participants quality of life
c Goal 3, reduce the participants care demands.
https://doi.org/10.1371/journal.pone.0223750.t004
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Limitations and challenges
There were several significant challenges in the design and undertaking of the study. First, a
case series modified ABA repeated measures design was chosen, rather than a double-blind
trial with sham and active stimulation phases. This was for several reasons: the rarity of PWS
and consequent likelihood of small sample size, the need to undertake the study in a naturalis-
tic setting resulting in the possibility for major differences between individual circumstances,
and uncertainty about the length of time in the active stimulation phase required before effects
might be seen, and the non-blind nature of the study imposed by the stimulus protocol requir-
ing stimulation to be detectable. The lack of a sham stimulation arm means that the possibility
that these marked improvements were a consequence of a placebo effect and/or because of
observer bias cannot be ruled out. However, significant improvements were only apparent
after nine months of stimulation for all four improved participants. In addition, although car-
ers were aware improvements may be delayed, similar patterns of improvement were reported
across three separate care settings (two participants resided together). In addition, these
observed improvements were informally reported to have continued months after the study
ended. These factors, together with homogeneous effect sizes, suggest improvements in behav-
iour are unlikely to be due to a placebo effect or a consequence of observer bias.
Secondly, we were dependent upon support staff for data collection using the daily behav-
iour diary. This was in addition to their normal data recording. Early after recruitment of two
participants it was apparent that the diaries were not being completed and we obtained ethical
approval and consent of the participants to use the daily records that staff routinely kept. This
same method of contemporaneous data collection (existing behavioural records) was used in
both phases for each participant ensuring consistency across baseline and active phases. Addi-
tionally, inter-rater reliability for this form of data collection in these two participants was
high.
Thirdly, a key inclusion criterion was that participants had temper outbursts. Compliance
was good for participants who completed the study (>86%), with all participants opting to
continue t-VNS post study end. However, inability to comply had a large impact on dropout
rates early in the baseline phase. Placement breakdown and/or change in support circumstance
was the main cause of drop out, suggesting that a facilitative care environment may be crucial
for t-VNS acceptability. It was partly for this reason that the length of baseline phases varied
between participants and also the active phase was extended to one year, ensuring improve-
ments were unlikely to be transient responses to changing circumstances. Indeed, a medica-
tion change during baseline for 005 may have contributed to reduced outbursts in active phase
one; however, this reduction was minor compared to the difference observed between baseline
and active phase four. This extension also ensured that for 009, insufficient stimulation dura-
tion was unlikely to be responsible for lack of improvement.
Finally, stimulation intensity in this study adhered to recommended t-VNS parameters.16
However, it is possible that different frequencies, pulse widths or amplitudes may more opti-
mally stimulate the vagus nerve.[28] It is important to note that t-VNS is licensed for the treat-
ment of depression and, although no participant met criteria for co-morbid mood disorder, a
moderating effect on mood may be implicated.
Future research
For t-VNS to become fully accepted as a treatment for behaviour problems in people with
PWS further studies are required. First, this study did not contain a sham condition. Future
work should if possible include a sham condition to account for any potential placebo effects
or observer bias that could have been present in this study. Secondly, this is a small study and
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replication is needed with an extension of the age-range of the participants downwards to
include children with PWS. Thirdly, further work is needed to refine the electrode design and
to develop strategies that maximises compliance in this group who have a history of problem
behaviours. Fourthly, additional data on the wider benefits of treatment on quality of life, ben-
eficial effects on family and/or paid carers, and savings on health and care costs are needed in
order to further build the case for making this treatment routinely available and funded
through the health insurance systems or national health services. Fifthly, in this study we opted
to use the stimulus protocol recommended for treating epilepsy but this may not be the opti-
mum for effective neuromodulation. Finally, an understanding of the mechanism of action is
required both to inform the stimulus protocol and also to determine whether this treatment
might be extended to other clinical groups with similar or related problem behaviours.
From the perspective of better understanding why problem behaviours are common among
people with PWS and also in those with other neurodevelopmental disorders this observation of
the beneficial effects of t-VNS indicates a need to move away from seeing them as primarily
shaped and re-inforced by experience but rather they are the result of impaired emotional regu-
lation that we suggest is a consequence of autonomic nervous system dysfunction and the
impact of such dysfunction centrally in the brain. The polyvagal theory[29] proposes that a
brainstem centre regulating the vagal nerve, often labelled the ventral vagal complex, acts as the
‘command centre’ for the vagal pathways mediating a calm behavioural state. Participants’
increase in ability to maintain calmness post t-VNS suggests that stimulating the vagal nerve’s
afferent pathways may partially ameliorate the function of potentially perturbed vagal pathways.
Woodcock et al. have proposed that change to routines or expectations place a higher than
normal cognitive load on individuals with PWS, due to a proposed deficit in attention shifting
ability, and it is the excess cognitive demand that results in loss of control.[3,7–9] Such rigidity
in thinking whilst dysfunctional may be a natural and adaptive response to feeling under threat
(e.g. in anxiety threat vigilance is increased[30] and induced anxiety is associated with cogni-
tive rigidity).[31] Consequently, what may seem to be a minor threat stimulus (a change in
environment) may trigger a full fight response in the form of an outburst, and is in line with
anecdotal reports[32] of the behaviour of monitoring fairness by people with PWS in resource
allocation in group living settings. One model would be that t-VNS produces a moderating
effect on emotional regulation, potentially by affecting the response to the high cognitive load
experienced by people with PWS under certain circumstances.
Increased vagal tone, and thus increase in parasympathetic activation may also be associ-
ated with changes in neurotransmitter systems, noradrenaline, acetylcholine (Ach), and
gamma-aminobutyric acid (GABA).[33] Of particular significance, tVNS has been associated
with increases in GABA being observed in patients with epilepsy after nine months of stimula-
tion[34] as well as elevated GABAergic motor cortical activity. [35] Rice et al. have also shown
that brain GABA levels were reduced in people with PWS who had emotional and behavioural
problems, including temper outbursts.[36] This evidence, coupled with this study’s findings
that t-VNS reduces such behaviours, suggests that the GABAergic system (in association with
vagal tone) may play an important role in mediating temper outbursts. Further studies are
required to explore these various explanations.
Conclusions
This study has demonstrated that VNS delivered by an external stimulus for four hours each
day has a significant therapeutic effect on temper outbursts in people with PWS that extends
to improvements in life more generally. Further analysis and investigation of the mechanisms
that underpin t-VNS’s efficacy on temper outbursts in PWS are required as are investigations
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into the optimum dose of t-VNS given the length of time before improvement and the beha-
vioural deterioration observed when the four-hour dose was halved. Future research should
also address the lack of a sham condition in this current study. All four people with PWS who
improved have continued treatment and the effect on their lives has been reported as
substantial.
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